Discover the impact that our work has on the UK cell and gene therapy industry.
It is our mandate to catalyse and facilitate growth in the cell and gene therapy industry. Since our inception in 2012, we have been gathering qualitative and quantitative data to showcase the impact we are having on the companies and researchers we work with and on general industry growth.
received by ATMP companies in the UK since 2012
increase in cleanroom footprint for manufacturing ATMPs in the UK since 2018
active clinical trials compared to 85 in 2018
in the sector in the UK compared to 540 in 2012
“Our agreement with CGT Catapult is an important strategic step that gives us the flexibility to scale our production capacity, which is crucial to the success of our business both near term, as we prepare for our first clinical trial with QEL-001, and longer term, as we advance our pipeline of novel engineered Treg cell therapies in neuroinflammatory and autoimmune diseases.”Ian McGill - Chief Executive Officer of Quell Therapeutics
“Collaboration is important in meeting the needs of this fast-moving sector. We worked closely with four customers in our early adopter program to pilot the new Quantum Flex platform.”Delara Motlagh, General Manager, Cell Therapy Technologies
“We are thrilled to be part of this consortium to support the continued innovation of cell therapy manufacturing processes. As a pioneer in the field of personalised cell therapies, we are excited to lend our expertise to this project which we believe can deliver significant benefits for patients.”Edward Samuel, EVP, Technical Operations at Achilles Therapeutics